Cell technology company iXCells Biotechnologies has partnered with Rosebud Biosciences to advance organoid-based models for rare diseases. The partnership will set out to develop a personalised, human-based approach for predicting drug safety and informing translational decision-making in rare diseases. iXCells will integrate Rosebud’s organoid generation and characterisation expertise into its existing iPSC solutions, enabling access to complex 3D human systems that […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!